Linked Data API

Show Search Form

Search Results

1700674
registered interest false more like this
date less than 2024-04-15more like thismore than 2024-04-15
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Tofersen: Licensing more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK. more like this
tabling member printed
Baroness Finlay of Llandaff more like this
uin HL3732 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> more like this
answering member printed Lord Markham more like this
grouped question UIN HL3733 more like this
question first answered
less than 2024-04-22T15:05:49.787Zmore like thismore than 2024-04-22T15:05:49.787Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1545131
registered interest false more like this
date less than 2022-11-23more like thismore than 2022-11-23
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Community Diagnostic Centres more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what NHS diagnostic and treatment hubs were established during 2022; what are their locations; what services each hub provides; how they were selected; and when each one became operational. more like this
tabling member printed
Lord Warner more like this
uin HL3732 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2022-12-15more like thismore than 2022-12-15
answer text <p>A table showing surgical hubs and community diagnostic centres (CDCs) established in 2022, with the services provided, the National Health Service region, the relevant integrated care system and NHS trust, the name of the hub and the date of opening, is attached due to the size of the data. Information on the selection criteria for each CDC and surgical hub is not held centrally.</p><p>Local systems undertake an evaluation of the most appropriate locations for CDCs, including consideration of accessibility, affordability and addressing inequality and deprivation. Business cases are scrutinised by a national approvals panel with clinical and diagnostic experts to assess feasibility prior to approval. CDC locations are also subject to Ministerial approval. Surgical hub locations have been selected by a clinically-led process to ensure that sites are connected to the appropriate services to deliver high quality outcomes for patients and to consider health inequalities. The independent sector were not invited to participate in the selection of CDCs or surgical hubs.</p><p>NHS England has engaged with patient forums and undertaken a public awareness campaign on the expansion of services. The Department and NHS England are working with general practitioners (GPs), cancer charities and patient representatives to expand direct GP access to diagnostic scans for those with concerning symptoms which do not align with the two-week cancer referral target to see a specialist.</p>
answering member printed Lord Markham more like this
grouped question UIN
HL3733 more like this
HL3734 more like this
HL3735 more like this
question first answered
less than 2022-12-15T13:11:30.843Zmore like thismore than 2022-12-15T13:11:30.843Z
answering member
4948
label Biography information for Lord Markham more like this
attachment
1
file name 2022 CDC and Hub locations.xlsx more like this
title 2022 CDC and Hub locations more like this
tabling member
1732
label Biography information for Lord Warner more like this